{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-003646","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2023-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.034108+00:00","generated_at":"2026-06-19T23:59:59.972403+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bioxytran receives CDSCO approval for first-in-human ProLectin-I trial","bullets":["India's CDSCO granted IND authorization (CT-06, No. CT/ND/03/2023) to evaluate ProLectin-I injection.","Trial will assess safety, tolerability, PK/PD; results to guide Phase II in Long COVID and IPF.","Separate approval from prior ProLectin-M authorization (Dec 2, 2022).","ProLectin-I targets viral persistence and fibrosis; Long COVID affects 65-100 million worldwide.","Trial at each site requires ethics committee approval before initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-003646","json":"https://secwatch.observer/filing/0001493152-23-003646.json","markdown":"https://secwatch.observer/filing/0001493152-23-003646.md","text":"https://secwatch.observer/filing/0001493152-23-003646.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315223003646/0001493152-23-003646-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315223003646/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T23:59:59.972403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}